---
title: "Changchun High-tech Subsidiary Receives FDA Orphan Drug Designation for GenSci128, Targeting Gastric Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280290825.md"
description: "Changchun High-tech's subsidiary, GenSci Pharmaceuticals, has received FDA orphan drug designation for GenSci128, a new chemical drug targeting gastric cancer. GenSci128 is a selective reactivator for the TP53 Y220C mutation, aimed at treating advanced solid tumors, including pancreatic, gastric, ovarian, breast, and colorectal cancers. It falls under the U.S. new drug registration category '505b1.'"
datetime: "2026-03-24T09:36:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280290825.md)
  - [en](https://longbridge.com/en/news/280290825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280290825.md)
---

# Changchun High-tech Subsidiary Receives FDA Orphan Drug Designation for GenSci128, Targeting Gastric Cancer

Changchun High-tech announced that its subsidiary, GenSci Pharmaceuticals, has received notification from the FDA granting orphan drug designation (ODD) for GenSci128, aimed at treating gastric cancer. According to Jin10, GenSci128 is classified as a new chemical drug under category 1 for therapeutic use and falls under the U.S. new drug registration category '505b1.' It is a selective reactivator targeting the TP53 Y220C mutation, intended for treating locally advanced or metastatic solid tumors carrying the TP53 Y220C mutation, including pancreatic cancer, gastric cancer, ovarian cancer, breast cancer, and colorectal cancer.

### Related Stocks

- [000661.CN](https://longbridge.com/en/quote/000661.CN.md)

## Related News & Research

- [00:18 ETDatar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren](https://longbridge.com/en/news/286712658.md)
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)